Loading...
Processa Pharmaceuticals, Inc.
PCSA•NASDAQ
Healthcare
Biotechnology
$0.21
$-0.00(-2.28%)
Processa Pharmaceuticals, Inc. (PCSA) Financial Performance & Income Statement Overview
Review Processa Pharmaceuticals, Inc.’s income statement, balance sheet, and cash flow reports with annual and quarterly breakdowns.
Revenue Growth
0.00%
Operating Income Growth
-5.19%
↓ 5.19%
Net Income Growth
-6.55%
↓ 6.55%
Operating Cash Flow Growth
-39.46%
↓ 39.46%
Operating Margin
0.00%
Gross Margin
0.00%
Net Profit Margin
0.00%
ROE
-319.58%
↓ 319.58%
ROIC
-342.78%
↓ 342.78%
Processa Pharmaceuticals, Inc. (PCSA) Income Statement & Financial Overview
Review Processa Pharmaceuticals, Inc.'s (PCSA) income statement with detailed quarterly and annual figures.
| Metric | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 |
|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Cost of Revenue | $0.00 | $3.42M | $139.00 | $2.81M |
| Gross Profit | $0.00 | -$3.42M | -$139.00 | -$2.81M |
| Gross Profit Ratio | ||||
| R&D Expenses | $1.71M | $2.29M | $1.73M | $1.54M |
| SG&A Expenses | $1.02M | $1.14M | $1.35M | $1.27M |
| Operating Expenses | $2.73M | $3.42M | $3.08M | $2.81M |
| Total Costs & Expenses | $2.73M | $3.42M | $3.08M | $5.62M |
| Interest Income | $6023.00 | $40150.00 | $0.00 | $83217.00 |
| Interest Expense | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation & Amortization | $301.00 | $203.00 | $139.00 | $139.00 |
| EBITDA | -$2.73M | -$3.42M | -$3.08M | -$2.81M |
| EBITDA Ratio | ||||
| Operating Income | -$2.73M | -$3.42M | -$3.08M | -$5.62M |
| Operating Income Ratio | ||||
| Other Income/Expenses (Net) | $6023.00 | $40150.00 | $71698.00 | $83217.00 |
| Income Before Tax | -$2.73M | -$3.38M | -$3.01M | -$2.73M |
| Income Before Tax Ratio | ||||
| Income Tax Expense | $0.00 | $0.00 | $0.00 | -$139.00 |
| Net Income | -$2.73M | -$3.38M | -$3.01M | -$2.73M |
| Net Income Ratio | ||||
| EPS | -$0.83 | -$1.03 | -$1.01 | -$1.10 |
| Diluted EPS | -$0.83 | -$1.03 | -$1.01 | -$1.10 |
| Weighted Avg Shares Outstanding | $3.70M | $3.28M | $2.98M | $2.47M |
| Weighted Avg Shares Outstanding (Diluted) | $3.70M | $3.28M | $2.98M | $2.47M |
Unlock 25+ Years of Financial Data
Get access to extended historical data, advanced metrics, and more with our premium plan